Milo A Puhan1, Nina Steinemann2, Christian P Kamm3, Stephanie Müller4, Jens Kuhle5, Roland Kurmann6, Pasquale Calabrese7, Jürg Kesselring8, Viktor von Wyl1. 1. Medical Faculty, University of Zurich, Switzerland. 2. Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland. 3. Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Switzerland / Department of Neurology, Cantonal Hospital Lucerne, Switzerland. 4. Department of Neurology, Cantonal Hospital St Gallen, Switzerland. 5. Department of Neurology, University Hospital Basel, Switzerland. 6. City of Winterthur, Switzerland. 7. Faculty of Psychology, University of Basel, Switzerland. 8. Department of Neurology, Kliniken Valens, Switzerland.
Abstract
QUESTION UNDER STUDY: Our aim was to assess whether a novel approach of digitally facilitated, citizen-science research, as followed by the Swiss Multiple Sclerosis Registry (Swiss MS Registry), leads to accelerated participant recruitment and more diverse study populations compared with traditional research studies where participants are mostly recruited in study centres without the use of digital technology. METHODS: The Swiss MS Registry is a prospective, longitudinal, observational study covering all Switzerland. Participants actively contribute to the Swiss MS Registry, from defining research questions to providing data (online or on a paper form) and co-authoring papers. We compared the recruitment dynamics over the first 18 months with the a priori defined recruitment goals and assessed whether a priori defined groups were enrolled who are likely to be missed by traditional research studies. RESULTS: The goal to recruit 400 participants in the first year was reached after only 20 days, and by the end of 18 months 1700 participants had enrolled in the Swiss MS Registry, vastly exceeding expectations. Of the a priori defined groups with potential underrepresentation in other studies, 645 participants (46.5%) received care at a private neurology practice, 167 participants (12%) did not report any use of healthcare services in the past 12 months, 32 (2.3%) participants lived in rural mountainous areas, and 20 (2.0% of the 1041 for whom this information was available) lived in a long-term care facility. Having both online and paper options increased diversity of the study population in terms of geographic origin and type and severity of disease, as well as use of health care services. In particular, paper enrolees tended to be older, more frequently affected by progressive MS types and more likely to have accessed healthcare services in the past 12 months. CONCLUSION: Academic and industry-driven medical research faces substantial challenges in terms of patient involvement, recruitment, relevance and generalisability. Digital studies and stakeholder engagement may have enormous potential for medical research. But many digital studies are based on limited participant information and/or informed consent and unclear data ownership, and are subject to selection bias, confounding and information bias. The Swiss MS Registry serves as an example of a digitally enhanced, citizen-science study that leverages the advantages of both traditional medical research, with its established research methods, and novel societal and technological developments, while mitigating their ethical and legal disadvantages and risks.
QUESTION UNDER STUDY: Our aim was to assess whether a novel approach of digitally facilitated, citizen-science research, as followed by the Swiss Multiple Sclerosis Registry (Swiss MS Registry), leads to accelerated participant recruitment and more diverse study populations compared with traditional research studies where participants are mostly recruited in study centres without the use of digital technology. METHODS: The Swiss MS Registry is a prospective, longitudinal, observational study covering all Switzerland. Participants actively contribute to the Swiss MS Registry, from defining research questions to providing data (online or on a paper form) and co-authoring papers. We compared the recruitment dynamics over the first 18 months with the a priori defined recruitment goals and assessed whether a priori defined groups were enrolled who are likely to be missed by traditional research studies. RESULTS: The goal to recruit 400 participants in the first year was reached after only 20 days, and by the end of 18 months 1700 participants had enrolled in the Swiss MS Registry, vastly exceeding expectations. Of the a priori defined groups with potential underrepresentation in other studies, 645 participants (46.5%) received care at a private neurology practice, 167 participants (12%) did not report any use of healthcare services in the past 12 months, 32 (2.3%) participants lived in rural mountainous areas, and 20 (2.0% of the 1041 for whom this information was available) lived in a long-term care facility. Having both online and paper options increased diversity of the study population in terms of geographic origin and type and severity of disease, as well as use of health care services. In particular, paper enrolees tended to be older, more frequently affected by progressive MS types and more likely to have accessed healthcare services in the past 12 months. CONCLUSION: Academic and industry-driven medical research faces substantial challenges in terms of patient involvement, recruitment, relevance and generalisability. Digital studies and stakeholder engagement may have enormous potential for medical research. But many digital studies are based on limited participant information and/or informed consent and unclear data ownership, and are subject to selection bias, confounding and information bias. The Swiss MS Registry serves as an example of a digitally enhanced, citizen-science study that leverages the advantages of both traditional medical research, with its established research methods, and novel societal and technological developments, while mitigating their ethical and legal disadvantages and risks.
Authors: Christian Philipp Kamm; L Barin; C Gobbi; C Pot; P Calabrese; A Salmen; L Achtnichts; J Kesselring; M A Puhan; V von Wyl Journal: J Neurol Date: 2019-10-08 Impact factor: 4.849
Authors: Chloé Sieber; Deborah Chiavi; Christina Haag; Marco Kaufmann; Andrea B Horn; Holger Dressel; Chiara Zecca; Pasquale Calabrese; Caroline Pot; Christian Philipp Kamm; Viktor von Wyl Journal: JMIR Mhealth Uhealth Date: 2022-10-05 Impact factor: 4.947
Authors: Rahim Lalji; Léonie Hofstetter; Alice Kongsted; Viktor von Wyl; Milo A Puhan; Cesar A Hincapié Journal: BMJ Open Date: 2022-07-13 Impact factor: 3.006
Authors: Marco Kaufmann; Jens Kuhle; Milo A Puhan; Christian P Kamm; Andrew Chan; Anke Salmen; Jürg Kesselring; Pasquale Calabrese; Claudio Gobbi; Caroline Pot; Nina Steinemann; Stephanie Rodgers; Viktor von Wyl Journal: Mult Scler J Exp Transl Clin Date: 2018-12-06
Authors: Laura Barin; Christian P Kamm; Anke Salmen; Holger Dressel; Pasquale Calabrese; Caroline Pot; Sven Schippling; Claudio Gobbi; Stefanie Müller; Andrew Chan; Stephanie Rodgers; Marco Kaufmann; Vladeta Ajdacic-Gross; Nina Steinemann; Jürg Kesselring; Milo A Puhan; Viktor von Wyl Journal: Mult Scler Date: 2019-01-18 Impact factor: 6.312
Authors: Anja I Lehmann; Stephanie Rodgers; Christian P Kamm; Mathias Mettler; Nina Steinemann; Vladeta Ajdacic-Gross; Marco Kaufmann; Jürg Kesselring; Pasquale Calabrese; Anke Salmen; Claudio Gobbi; Chiara Zecca; Georg F Bauer; Viktor von Wyl Journal: J Neurol Date: 2020-06-11 Impact factor: 4.849
Authors: Vladeta Ajdacic-Gross; Nina Steinemann; Gábor Horváth; Stephanie Rodgers; Marco Kaufmann; Yanhua Xu; Christian P Kamm; Jürg Kesselring; Zina-Mary Manjaly; Chiara Zecca; Pasquale Calabrese; Milo A Puhan; Viktor von Wyl Journal: Front Neurol Date: 2021-07-06 Impact factor: 4.003
Authors: Marco Kaufmann; Milo Alan Puhan; Anke Salmen; Christian P Kamm; Zina-Mary Manjaly; Pasquale Calabrese; Sven Schippling; Stefanie Müller; Jens Kuhle; Caroline Pot; Claudio Gobbi; Nina Steinemann; Viktor von Wyl Journal: Front Neurol Date: 2020-03-06 Impact factor: 4.003